ESMO Publishes New Position Paper on Supportive and Palliative Care

Food and Healthcare Press Releases Friday December 15, 2017 15:00
LUGANO, Switzerland--15 Dec--PRNewswire/InfoQuest

ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care [ https://doi.org/10.1093/annonc/mdx757   ], calling attention to the evolving and growing gap between the needs of cancer patients and the actual provision of patient-centred care.

"New studies show that there may be a gap between what doctors think is important for patients, and what patients really need [ http://www.esmo.org/Conferences/Past-Conferences/ESMO-2017-Congress/Press-Media/Press-Releases/Patients-Feel-Psycho-social-Impact-of-Chemo-More-Acutely-Than-Physical-Side-Effects   ] . With this position paper, we wanted to call attention to the fact that, as well as anti-tumour treatment, cancer patients need physical, psychological, social, spiritual support, at every stage of the disease, from diagnosis," said main author Karin Jordan, ESMO Faculty Coordinator.

Matti Aapro, co-author, MASCC Past-president, said: "Recent studies [ http://esmo.org/Conferences/Past-Conferences/ESMO-2017-Congress/Press-Media/Press-Releases/Triggers-a-New-Tool-to-Assess-Cancer-Patients-Palliative-Needs   ] show that palliative and supportive care not only improves treatment: it contributes to better use of existing resources, avoids waste and may also reduce the cost of treatment."

Patient reported outcomes should be highly encouraged as shown to be associated with better quality of life, fewer hospitalisations and even increased survival, compared with usual care.

"We hope that this paper will contribute to develop a generalised culture and acceptance of supportive and palliative care, worldwide," said Aapro. "Basic patient needs such as pain relief are still not being widely met [ http://www.esmo.org/Policy/Global-Opioid-Policy-Initiative   ]. Education is vital to make sure that essential supportive care is accessible to all cancer patients, everywhere."

ESMO position paper content:
  • Key patient-centred care interventions and training
  • End-of-life care
  • Role of multidisciplinary teams
  • Integrating healthcare resources
  • Research and resources in supportive and palliative care
Full story:   http://bit.ly/2AiD5qG

ESMO is the leading professional organisation for medical oncology. With 17,000 members representing oncology professionals from 150 countries worldwide, ESMO is the society of reference for oncology education and information.

media@esmo.org
+41-91-973-19-07
Source: European Society for Medical Oncology (ESMO)

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics